One possible explanation for the observed interaction between age and the ER-negative breast cancer PRS in BRCA1 mutation carriers could due to the use of the ER-negative breast cancer PRS from the general population to predict the risk of overall breast cancer risk for BRCA1 mutation carriers. This evidence concerns the gene BRCA1 and breast carcinoma.